BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Sarcoma clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for sarcoma: 151 (124 sponsors; 20 newly posted in the last 180 days, 12 stopped in the last 180 days; 14 new-entrant sponsors). Momentum score 4.6, rank 88 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 4, Phase 1 57, Phase 2 64, Phase 3 8, Phase 4 1, N/A 17.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN3NA 1, P3 1, P2 100
Merck Sharp & Dohme LLC MRK3P2 2, P3 100
Advenchen Laboratories, LLC1P3 100
Intensity Therapeutics, Inc. INTS1P3 100
Ionis Pharmaceuticals, Inc. IONS1P3 100
PharmaMar1P3 100
Sinocelltech Ltd.1P3 100
Takara Bio Inc.1P3 100
Alpha Tau Medical LTD. DRTS4NA 403
USWM CT, LLC4P2 3, P1 100
Eli Lilly and Company LLY3P2 2, P1 100
Hoffmann-La Roche3P1 2, P2 110
Novartis Pharmaceuticals NVS3NA 1, P1 210
Advenchen Pharmaceuticals, LLC. new entrant2P2 220
Amgen AMGN2P1 201
Ascentage Pharma Group Inc. AAPG2P2 200
Bristol-Myers Squibb BMY2P1 1, P2 100
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2P2 200
GlaxoSmithKline2P2 210
Hansoh BioMedical R&D Company2P2 1, P1 101
Hexin (Suzhou) Pharmaceutical Technology Co., Ltd new entrant2P1 1, P2 122
Lantheus Medical Imaging LNTH2P2 200
MedPacto, Inc.2P2 1, NA 111
Turning Point Therapeutics, Inc. TPB2P2 200
Actithera INC. new entrant1P2 110

New-entrant sponsors: Advenchen Pharmaceuticals, LLC., Hexin (Suzhou) Pharmaceutical Technology Co., Ltd, Actithera INC..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-01 est.P2EpicentRx, Inc.NCT04673942 A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid TumorsSolid Tumor, Adult; Cancer; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Chondrosarcomaactive not recruiting140
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P2Hexin (Suzhou) Pharmaceutical Technology Co., LtdNCT07920835 A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT ImagingSoft Tissue Sarcomarecruiting60
2027-01 est.P2QBiotics Group LimitedNCT05755113 A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue SarcomaSoft Tissue Sarcomarecruiting40

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2027-04-14PDUFA date (company-disclosed)pendingInhibrx Biosciences, Inc. INBXPDUFA April 14, 2027 - Inhibrx Biosciences, Inc.
2026-11-30PDUFA date (company-disclosed)pendingCogent Biosciences, Inc. COGTbezuclastinibPDUFA November 30, 2026 - Cogent Biosciences, Inc. (bezuclastinib)

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-13 est.P1/P2GlaxoSmithKlineNCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerMelanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinactive not recruiting83
2026-10-01 est.P1/P2USWM CT, LLCNCT05642455 SPEARHEAD-3 Pediatric StudySynovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma (NBL); Osteosarcomarecruiting20
2026-09-22 est.P1/P2ImmVira Pharma Co. LtdNCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or MeSolid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLCrecruiting30
2026-07-03 est.P3Boehringer IngelheimNCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS)withdrawn
2026-06-17P3Hansoh BioMedical R&D CompanyNCT06935409 Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureOsteosarcomacompleted122
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06500091 TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid TumorsSoft Tissue Sarcoma; Melanomanot yet recruiting54
2026-06 est.P1/P2Volastra Therapeutics, Inc.NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerAdvanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancerrecruiting200
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350
2026-05-25P3Polaris Group PIINCT05712694 Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)Soft Tissue Sarcomaterminated218

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "sarcoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.